Alzheimer's Disease research is converging on a multi-pronged strategy that couples molecular-level neuroimmune modulation with non-invasive neurostimulation and refined clinical/diagnostic frameworks. At the biological core, exosomes and extracellular vesicles (EVs) emerge as central actors bridging pathogenesis and therapeutics: they cross the blood-brain barrier, inhibit A1 astrocyte transformation, rebalance Treg/Th17 subsets, suppress the NLRP3 inflammasome, and shift cytokine profiles (reducing IL-1β, TNF-α, IL-6 while elevating IL-10), while also enhancing Aβ clearance via phagocytosis and autophagy. Sourced from mesenchymal stem cells, immune cells, or traditional Chinese medicines, and prized for high biocompatibility and low immunogenicity, exosomes are being engineered as targeted drug-delivery carriers—though biodistribution control and immune clearance remain key translational hurdles. In parallel, EVs derived from cerebral tissue and detectable in peripheral blood are being validated as diagnostic biomarkers, exemplified by their assay in the Down syndrome/Vitamin E cohort alongside cognitive endpoints (Brief Praxis Test, vocabulary, behavior/function scores), positioning EVs as a liquid-biopsy strategy for tracking preclinical neurodegeneration.
A second trajectory centers on non-pharmacological neuromodulation, specifically transcranial vibrotactile stimulation at 40 Hz and 80 Hz, which improves cognitive performance and hippocampal cholinergic function through frequency-dependent mechanotransduction. This mechanical stimulus triggers downstream memory signaling cascades (PI3K, AKT, ERK1/2, CREB, CAMK4), upregulating memory-related gene expression and offering a therapeutic adjunct for cholinergic dysfunction—a pathway also disrupted by microglial hyperactivation and oxidative stress in AD. Complementing this, biomarker discovery continues to mature, with sphingomyelins and plasma T-tau showing correlation specifically in amyloid-positive, cognitively unimpaired individuals, reinforcing lipid and tau-based panels as early, non-invasive indicators of preclinical Alzheimer's neurodegeneration tied to cortical amyloid-beta burden.
Underlying these biological and technological advances is a growing recognition that glial crosstalk, complement activation, and metabolic/oxidative stress form a self-amplifying loop sustaining neuroinflammation—positioning EVs and exosomes as both disruptors of this cycle and vehicles for its therapeutic correction. Nanomedicine broadly is enabling more precise targeted drug delivery, extending the exosome paradigm toward synthetic and hybrid carrier systems.
Finally, the field is grappling with translational and societal dimensions: evolving diagnostic criteria for AD and its behavioral variants risk creating clinician and public uncertainty, prompting socio-ethical interventions targeted at health workers and the general public to reduce misunderstanding and potential harm. Together, these threads depict a trend toward integrated AD management—combining EV/exosome-based immunomodulatory and diagnostic platforms, mechanotransduction-based cognitive enhancement, refined fluid/imaging biomarkers, and deliberate efforts to align diagnostic clarity with caregiver awareness and clinical practice.